The current understanding is that HSP60 oral administration protects from atherosclerosis due to the HSP60-induced mucosal immune tolerance, whereas subcutaneous injection promotes atherosclerosis progression [12,31–33]. This evidence concerns the gene HSPD1 and atherosclerosis.